TP53 and neoplasm: While increasing mutational load through alterations in tumour suppressors like p53 should amplify the number of neoantigens and sensitise tumours to the immune system, these mutations can also drive mutations in antigen‐presenting pathways and/or in key cellular machineries that can trigger transcriptional and metabolic changes that in turn have indirect effects on tumour‐infiltrating immune cells.